A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma
This open-label Phase 1 study will evaluate the safety, tolerability, PK characteristics and preliminarily efficacy of JMKX003948 tablets in patients with renal cell carcinoma.
Renal Cell Carcinoma Metastatic
DRUG: JMKX003948
Dose Escalation: Number of participants with dose limiting toxicities (DLTs), Number of participants with DLTs, Up to 2 months|Dose Escalation: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), Number of participants with AEs/SAEs to characterize the safety and tolerability of JMKX003948., Up to 2 years|Dose Expansion: Objective Response Rate (ORR), ORR defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1., Up to 1 year
maximum plasma concentration (Cmax), Maximum observed concentration., Up to 1 month|maximum plasma concentration (Tmax), Time to reach maximum observed plasma concentration., Up to 1 month|Duration of Response (DoR), DoR is defined as the time from the date of first documented CR or PR, assessed by investigator and based on RECIST v. 1.1, to the documented date of progressive disease (PD) or death, whichever occurred first., Up to 1 year
This open-label Phase 1 study will evaluate the safety, tolerability, PK characteristics and preliminarily efficacy of JMKX003948 tablets in patients with renal cell carcinoma.